- Presentation Titles Include: Oral Enclomid (Androxal®) Raises Free and Total Serum Testosterone in Hypogonadal Men: Comparison with a Topical Gel Oral Enclomid (Androxal®) Raises Free and Total Serum Testosterone in Hypogonadal Men and Does Not Lower Sperm Counts: Comparison with a Topical Gel Oral Enclomid (Androxal®) Raises Serum Testosterone and Estrogen in Hypogonadal Men and May Have Favorable Effects on Bone Mineral Density
Key conclusions from the presentations:
- Confirmation that Androxal can provide consistent and effective therapy in men with secondary hypogonadism. There is no deleterious effect on spermatogenesis.
- The comparative data show that restoration of testosterone with topical testosterone is more variable and there is clinically significant suppression of spermatogenesis.
- Androxal may have a positive effect on bone mineral deposition.
- Overall, the data presented confirm that Androxal can provide effective therapy in men with secondary hypogonadism, particularly in those wishing to preserve reproductive status.
THE WOODLANDS, Texas, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced that the Sexual Medicine Society of North America (SMSNA) has accepted key data on Androxal® for presentation at the annual meeting in New Orleans, Louisiana, November 21 – 24, 2013. The data presented are from subset analyses of the double-blind, placebo and active control Phase 2 and 3 studies.
One presentation describes the basic clinical profile of Androxal. Androxal acts at the level of the pituitary as a selective estrogen receptor modulator (SERM) to block the negative feedback of estrogen on the pituitary hormones, LH and FSH. Restoration of LH (secondary hypogonadal males have low levels) is shown to provide rapid and effective normalization of T levels without excursion outside the normal range. This profile is in contrast to the topical agents used in the protocol.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV